Biallelic COX10 Mutations and PMP22 Deletion in a Family With Leigh Syndrome and Hereditary Neuropathy With Liability to Pressure Palsy
Citation Manager Formats
Make Comment
See Comments

Abstract
Objectives Leigh syndrome is a progressive encephalopathy characterized by symmetrical lesions in brain. This study aimed to investigate the clinicopathologic and genetic characteristics of a family with Leigh syndrome and hereditary neuropathy with liability to pressure palsy (HNPP).
Methods Data from a Japanese family's clinical features, MRIs, muscle biopsy, and an autopsy were analyzed. A whole-exome sequence was performed, as well as real-time PCR analysis to determine copy number variations and Western blot analyses.
Results The proband and her 2 siblings developed spastic paraplegia and mental retardation during childhood. The proband and her sister had peripheral neuropathy, whereas their father developed compression neuropathy. Leigh encephalopathy was diagnosed neuropathologically. Brain MRI revealed changes in cerebral white matter as well as multiple lesions in the brainstem and cerebellum. Muscle biopsy revealed type 2 fiber uniformity and decreased staining of cytochrome c oxidase. The COX10 missense mutation was identified through whole-exome sequence. A 1.4-Mb genomic deletion extending from intron 5 of COX10 to PMP22 was detected.
Discussion These findings suggest that in this family, Leigh syndrome is associated with a mitochondrial respiratory chain complex IV deficiency caused by biallelic COX10 mutations coexisting with HNPP caused by heterozygous PMP22 deletion.
Leigh syndrome is a group of clinically heterogeneous conditions with widely varying clinical manifestations.1,-,3 More than 75 causative genes have been identified in Leigh syndrome.4 The diagnosis of Leigh syndrome is challenging due to the wide range of clinical manifestations. We present the clinicopathologic and genetic characteristics of a family with Leigh syndrome coexisting with hereditary neuropathy with liability to pressure palsy (HNPP).
Clinical Characteristics
Table 1 summarizes the family's clinical characteristics. Patients 1 (III-1, eFigure 1, links.lww.com/NXG/A545) and 3 (III-3) presented with spastic paraplegia, intellectual disability, cerebellar ataxia, and respiratory failure. Brain MRI for patient 1 revealed diffuse high-intensity lesions with coarsening and vacuolization in the white matter (eFigure 2, A–F) as well as multiple lesions in the brainstem and cerebellum (eFigure 2, G–I). Patients 1 and 3 had marked peripheral neuropathy. Patient 4 (II-5) developed compression neuropathy after surgery (eTable 1).
Summary of Clinical and Genetic Findings of the Affected Member of the Family
Histology and Respiratory Chain Enzyme Activity of Biopsied Muscle
A biopsy specimen from patient 1 revealed variation in muscle fiber diameter (eFigure 3A, links.lww.com/NXG/A545). A moderate increase in lipid was found in muscle fibers (eFigure 3B). Modified Gomori trichrome staining revealed no ragged-red fibers (eFigure 3C). COX activity was found to be reduced in a widespread and severe manner (eFigure 3, D and E). The uniform staining pattern of type 2 fibers was revealed by ATPase histochemistry (eFigure 3F).
Measurement of respiratory chain complex enzyme activity in biopsied muscle revealed that the levels of all enzymes were lower than those in normal tissues (eTable 2, links.lww.com/NXG/A545).5 The enzyme activity in fibroblast revealed a selective decrease in complex IV (eTable 2). The results of the enzymes were consistent with complex IV deficiency.
Autopsy Findings
An autopsy was performed on patient 3 (III-3) at age 9 years. The brain showed diffuse and severe white matter degeneration (Figure 1, A and B). The loss of myelin and axons appeared to be similar in extent in the degenerated white matter (Figure 1, C and D), and vacuolar changes of the neuropil accompanied by gliosis were observed (Figure 1E). Atrophy and myelin pallor was also evident in the cerebellar white matter, middle cerebellar peduncles, and pontine base (Figure 1F). Spotty demyelinating lesions were found in the left medial lemniscus (Figure 1F) and the reticular formation of the medulla oblongata (Figure 1, G and H). Axons were relatively preserved in both lesions, as well as the ventral part of the medulla oblongata, despite the significant loss of myelin (Figure 1, I and J). Olivary hypertrophy with severe gliosis (Figure 1K), Purkinje cell loss in the cerebellar cortex, and gliosis in the dentate nucleus (Figure 1L) were evident.
(A) The brain weight was 1,100 g. A coronal section of the left cerebral hemisphere showed marked volume loss and grayish discoloration of the white matter. Severely softened deep white matter with cavity-like changes (arrow). (B) Diffuse myelin pallor in the affected white matter. U-fibers are mostly spared. (C and D) Myelin (C) and axons (D) are depleted to similar extents accompanied by some swelling axons in the moderately affected parietal white matter. (E) Neuropil vacuolar changes with gliosis and macrophage infiltration (inset) in relatively preserved white matter of the frontal lobe. (F) Atrophy and myelin pallor of the cerebellar white matter, middle cerebellar peduncles, and pontine base. A spotty demyelinating lesion in the left medial lemniscus (arrowhead). (G) Diffuse myelin pallor of the ventral part of medulla oblongata with bilateral olivary hypertrophy. A spotty demyelinating lesion crossing the midline raphe (arrow). (H) A high-magnification image was taken from the demyelinating lesion indicated by an arrow in (G). Tissue rarefaction and neuropil vacuolation are visible, and capillary prominence, gliosis, and macrophage infiltration are evident. Some neurons are relatively preserved in the lesion (triangles). (I and J) Images taken from the same lesion pointed with an arrow in (G). In the myelin basic protein (MBP) severely depleted lesion (I arrow), SMI-31-labeled axons are relatively preserved (J arrow). (K) Neuronal loss with marked gliosis in the inferior olivary nucleus. (L) Mild neuropil vacuolar changes accompanied by capillary prominence and gliosis in the dentate nucleus. (B, C, F, and G) Klüver-Barrera, and (E, H, K, and L) hematoxylin and eosin staining, (D and J) SMI-31, and (I) MBP immunohistochemistry. Bar = 145 μm for C and D, 50 μm for E, K, and L, 16 μm for inset in E, 43 μm for H, and 400 μm for I and J.
Genetic Analysis
Whole-exome sequence analysis showed COX10 variants of p.Arg159Gln and novel p.Pro295Leu in patients 1 and 3 (Figure 2A). An in silico analysis suggested that the p.Pro295Leu variant was pathogenic, whereas the p.Arg159Gln was predicted to be benign (eTable 3, links.lww.com/NXG/A545). CNV analysis of COX10 revealed a decreased gene dosage, indicating the presence of a deletion in patients 1, 3, and 4 (Figure 2B). Furthermore, CNV analysis revealed a decreased gene dosage in PMP22 (Figure 2C). A DNA microarray analysis revealed an approximately 1.4-Mb deletion spanning from intron 6 of COX10 to PMP22 (Figure 2D).
(A) Electropherograms of the p.Pro295Leu missense mutation in exon 6 of COX10 in patients 1 and 3 and their mother are shown. There were no pathogenic mitochondrial mutations in this family. (B) A CNV analysis of COX10 revealed a decreased gene dosage in intron 6 and exon 7 of COX10 in patients 1 (III-1), 3 (III-3), and 4 (II-5). The results are presented as the mean ± SEM (n = 3). (C) Decreases in CNV in PMP22 in patients 1 (III-1), 3 (III-3), and 4 (II-5). The results are presented as the mean ± SEM (n = 3). (D) Microarray analysis of patient 1 (III-1) revealed an approximately 1.4-Mb deletion extending from COX10 intron 5 to PMP22 (hg19 chr17: 14,087,933–15,484,859; 1,397 kbp). The deletion is predicted to result in a truncated COX10 lacking 130 amino acids at its C-terminus. CNV = copy number variant.
Protein Analysis
Proteins were extracted from the frozen tissue (cerebral cortex and white matter) in patient 3. In both mitochondrial and total lysate fractions, Western blot analysis revealed decreased expression levels of the COX1/MT-CO1, COX2/MT-CO2, and COX4 complex IV subunits (eFigure 4, A and B, links.lww.com/NXG/A545).
Discussion
In this study, we identified a family with Leigh syndrome coexisting with HNPP caused by biallelic COX10 mutations and heterozygous PMP22 deletion. An enzyme activity analysis revealed that mitochondrial respiratory chain complex IV deficiency is the cause of Leigh syndrome in this family, which is most likely caused by biallelic COX10 mutations composed of novel missense mutation and partial deletion (eFigure 5, links.lww.com/NXG/A545).
Peripheral neuropathy was observed in patients 1 and 3, and compression neuropathy was noted in their father (patient 4). We identified a deletion of PMP22, which is cosegregated with neuropathy in the family (eFigure 5, links.lww.com/NXG/A545). We report the patients of Leigh syndrome with neuropathy associated with PMP22 deletion and COX10 mutation. COX10 is located in the vicinity of PMP22 and has a CMT1A-repeat sequence that is highly similar to that of PMP22 (eFigure 6).6 The presence of such a sequence suggests a mechanism for homologous recombination.7 Genetic rearrangements resulting in HNPP deletion disrupted 1 copy of COX10 on the recombinant allele. If the pathologic mutation of COX10 coexists in the other allele, a patient with HNPP could develop Leigh syndrome, as was observed in our family.
Study Funding
This study was partly supported by AMED JP22dk0207060 and KAKENHI 22H02980 (to T.I.) and AMED JP21ek0109468 and JP19ek0109273 (to M.K.).
Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NG for full disclosures.
Acknowledgment
The authors thank the patients and their family members whose participation made this work possible. The authors also thank Drs. Shuichi Igarashi, Motoyoshi Yamazaki, and Yoji Onishi for kindly providing valuable clinical information.
Appendix Authors

Footnotes
↵* These authors contributed equally to this work as co–first authors.
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the AMED.
- Received April 6, 2022.
- Accepted in final form July 26, 2022.
- Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.